Educational information only. Not medical advice. Compounds discussed may be research-use-only and are not intended for human or veterinary consumption unless specifically approved and prescribed through appropriate channels.
🔬 Research Hub
Your central directory for compound profiles, research hubs, lab tools, and educational resources. Everything organized by category — find what you need, backed by source-cited evidence.
💉 GLP-1 & Metabolic Compounds
Semaglutide
GLP-1 receptor agonist with ~7-day half-life. FDA approved (Ozempic®, Wegovy®, Rybelsus®). STEP 1 trial: 14.9% mean weight loss. SELECT trial: significant MACE reduction in non-diabetic CVD patients.
Tirzepatide
GLP-1/GIP dual agonist. FDA approved (Mounjaro®, Zepbound®). SURMOUNT-1: 20.9% mean weight loss at 72 weeks — highest of any approved medication at time of approval.
Retatrutide
Investigational GLP-1/GIP/Glucagon triple agonist. Phase II: 24.2% mean weight loss — highest pharmacological weight loss reported to date. Phase III active.
🧬 Tissue Repair & Recovery Peptides
BPC-157
15-amino acid gastric peptide fragment. 400+ indexed preclinical studies. Research areas: GI repair, tendon/ligament healing, angiogenesis, nitric oxide pathways. Oral bioavailability documented for GI endpoints.
TB-500 (Thymosin β4)
Thymosin beta-4 synthetic analog. Studied for wound healing, angiogenesis, cardiomyocyte protection, and muscle repair. Actin polymerization modulation and anti-inflammatory mechanisms.
Thymosin Alpha-1
28-aa thymic peptide. Approved in 35+ countries (Zadaxin®) for hepatitis B/C and cancer immunotherapy adjunct. Among the most evidence-backed peptides with genuine Phase III data.
🧠 Nootropic & Neuropeptide Research
Semax
ACTH(4-7) analog. Russian-approved for stroke and cognitive impairment. Studied for BDNF upregulation, neuroprotection in ischemia, attention, and memory. Limited Western trial data.
NMN / NAD+ Pathway
NAD+ biosynthesis precursor. Multiple human trials confirm blood NAD+ elevation. Sirtuin pathway activation, mitochondrial function, and DNA repair investigated. Phase II trials for aging endpoints ongoing.
PT-141 (Bremelanotide)
Cyclic melanocortin receptor agonist. FDA approved as Vyleesi® for HSDD — one of the only research peptides to achieve full FDA approval. Acts centrally via MC3R/MC4R.
⚗️ Lab Calculators & Tools
Reconstitution Calculator
BAC water volume → concentration → draw units
Blend Calculator
Multi-compound blend math and ratios
mg / mcg Converter
Mass unit conversions with U-100 mapping
mL / Units Converter
Volume to insulin units and back
Vial Planning Calculator
Total draws per vial at any dose
Compare Compounds
Side-by-side compound comparison tool
📚 Learn & Reference
📋 First-Timer’s Research Guide
Reconstitution, COA verification, supply checklist, storage, and lab math — start here.
⚠️ Vendor Red Flags Guide
How to spot fake COAs, underdosed vials, and vendor fraud — 6 major red flags explained.
📖 Research Glossary
Searchable definitions for peptide, GLP-1, and nootropic research terminology.
💉 GLP-1 Research Hub
Deep-dive on GLP-1 receptor agonists — mechanism, trial data, comparison tables.
🧬 Peptide Research Hub
Evidence profiles for tissue repair, immune, and endocrine peptides.
🧠 Nootropic Research Hub
Cognitive compounds, NAD+ pathway, racetams, and neuropeptides by evidence tier.